标题
Taxane anticancer agents: a patent perspective
作者
关键词
-
出版物
EXPERT OPINION ON THERAPEUTIC PATENTS
Volume 26, Issue 1, Pages 1-20
出版商
Informa Healthcare
发表日期
2015-12-11
DOI
10.1517/13543776.2016.1111872
参考文献
相关参考文献
注意:仅列出部分参考文献,下载原文获取全部文献信息。- Larotaxel (L) in combination with trastuzumab in patients with HER2 + metastatic breast cancer (MBC): Interim analysis of an open phase II label study
- (2017) V. Dieras et al. JOURNAL OF CLINICAL ONCOLOGY
- Phase I dose-ranging, pharmacokinetic (PK) study of tesetaxel, a novel orally active tubulin-binding agent.
- (2017) M. Beeram et al. JOURNAL OF CLINICAL ONCOLOGY
- A phase II study of paclitaxel poliglumex (PPX), temozolamide (TMZ), and radiation (RT) for newly diagnosed high-grade gliomas.
- (2017) S. A. Jeyapalan et al. JOURNAL OF CLINICAL ONCOLOGY
- A randomized study of ganetespib, a heat shock protein 90 inhibitor, in combination with docetaxel versus docetaxel alone for second-line therapy of lung adenocarcinoma (GALAXY-1).
- (2017) Suresh S. Ramalingam et al. JOURNAL OF CLINICAL ONCOLOGY
- Design, synthesis and biological evaluation of a highly-potent and cancer cell selective folate–taxoid conjugate
- (2015) Joshua D. Seitz et al. BIOORGANIC & MEDICINAL CHEMISTRY
- Novel Actions of Next-Generation Taxanes Benefit Advanced Stages of Prostate Cancer
- (2015) R. de Leeuw et al. CLINICAL CANCER RESEARCH
- Principles in the design of ligand-targeted cancer therapeutics and imaging agents
- (2015) Madduri Srinivasarao et al. NATURE REVIEWS DRUG DISCOVERY
- Phase III trial of nonpegylated liposomal doxorubicin in combination with trastuzumab and paclitaxel in HER2-positive metastatic breast cancer
- (2014) J. Baselga et al. ANNALS OF ONCOLOGY
- Phase III study (MONET1) of motesanib plus carboplatin/paclitaxel in patients with advanced nonsquamous nonsmall-cell lung cancer (NSCLC): Asian subgroup analysis
- (2014) K. Kubota et al. ANNALS OF ONCOLOGY
- Phase I clinical and pharmacokinetic study of ombrabulin (AVE8062) combined with cisplatin/docetaxel or carboplatin/paclitaxel in patients with advanced solid tumors
- (2014) Rastislav Bahleda et al. INVESTIGATIONAL NEW DRUGS
- Multifunctional, stimuli-sensitive nanoparticulate systems for drug delivery
- (2014) Vladimir P. Torchilin NATURE REVIEWS DRUG DISCOVERY
- The synthesis of novel taxoids for oral administration
- (2013) Yun-rong Jing et al. BIOORGANIC & MEDICINAL CHEMISTRY
- Pertuzumab: A Review of Its Use for First-Line Combination Treatment of HER2-Positive Metastatic Breast Cancer
- (2013) Paul L. McCormack DRUGS
- Pertuzumab, trastuzumab, and docetaxel for HER2-positive metastatic breast cancer (CLEOPATRA study): overall survival results from a randomised, double-blind, placebo-controlled, phase 3 study
- (2013) Sandra M Swain et al. LANCET ONCOLOGY
- Increased Survival in Pancreatic Cancer with nab-Paclitaxel plus Gemcitabine
- (2013) Daniel D. Von Hoff et al. NEW ENGLAND JOURNAL OF MEDICINE
- Larotaxel with Cisplatin in the First-Line Treatment of Locally Advanced/Metastatic Urothelial Tract or Bladder Cancer: A Randomized, Active-Controlled, Phase III Trial (CILAB)
- (2013) Cora N. Sternberg et al. ONCOLOGY
- Engineering Folate–Drug Conjugates to Target Cancer: From Chemistry to Clinic
- (2012) Iontcho R. Vlahov et al. BIOCONJUGATE CHEMISTRY
- A critical review of lipid-based nanoparticles for taxane delivery
- (2012) Lan Feng et al. CANCER LETTERS
- Cabazitaxel: More Than a New Taxane for Metastatic Castrate-Resistant Prostate Cancer?
- (2012) A. C. Mita et al. CLINICAL CANCER RESEARCH
- Liposomal paclitaxel formulations
- (2012) Štěpán Koudelka et al. JOURNAL OF CONTROLLED RELEASE
- Synthesis and biological evaluation of novel 3′-difluorovinyl taxoids
- (2012) Larissa Kuznetsova et al. JOURNAL OF FLUORINE CHEMISTRY
- Neoadjuvant Paclitaxel Poliglumex, Cisplatin, and Radiation for Esophageal Cancer
- (2011) Thomas Dipetrillo et al. AMERICAN JOURNAL OF CLINICAL ONCOLOGY-CANCER CLINICAL TRIALS
- Taxane-Induced Blockade to Nuclear Accumulation of the Androgen Receptor Predicts Clinical Responses in Metastatic Prostate Cancer
- (2011) M. S. Darshan et al. CANCER RESEARCH
- Tumor-targeting drug delivery of new-generation taxoids
- (2011) Iwao Ojima et al. Future Medicinal Chemistry
- Second-generation taxanes effectively suppress subcutaneous rat lymphoma: role of disposition, transport, metabolism, in vitro potency and expression of angiogenesis genes
- (2011) Berta Otová et al. INVESTIGATIONAL NEW DRUGS
- Randomized, Double-Blind, Placebo-Controlled Phase II Study of AMG 386 Combined With Weekly Paclitaxel in Patients With Recurrent Ovarian Cancer
- (2011) Beth Y. Karlan et al. JOURNAL OF CLINICAL ONCOLOGY
- Phase 3 study of docosahexaenoic acid-paclitaxel versus dacarbazine in patients with metastatic malignant melanoma
- (2010) A. Y. Bedikian et al. ANNALS OF ONCOLOGY
- Mechanism-Based Tumor-Targeting Drug Delivery System. Validation of Efficient Vitamin Receptor-Mediated Endocytosis and Drug Release
- (2010) Shuyi Chen et al. BIOCONJUGATE CHEMISTRY
- Adjuvant dose-dense doxorubicin plus cyclophosphamide followed by dose-dense nab-paclitaxel is safe in women with early-stage breast cancer: a pilot study
- (2010) Nicholas Robert et al. BREAST CANCER RESEARCH AND TREATMENT
- Phase II Trial of Weekly Nanoparticle Albumin-Bound Paclitaxel With Carboplatin and Trastuzumab as First-line Therapy for Women With HER2-Overexpressing Metastatic Breast Cancer
- (2010) Alison K. Conlin et al. Clinical Breast Cancer
- In Vitro and In Vivo Antitumor Efficacy of Docetaxel and Sorafenib Combination in Human Pancreatic Cancer Cells
- (2010) P. Ulivi et al. CURRENT CANCER DRUG TARGETS
- Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial
- (2010) Johann Sebastian de Bono et al. LANCET
- New-generation taxoid SB-T-1214 inhibits stem cell-related gene expression in 3D cancer spheroids induced by purified colon tumor-initiating cells
- (2010) Galina I Botchkina et al. Molecular Cancer
- Cabazitaxel
- (2010) Matthew D. Galsky et al. NATURE REVIEWS DRUG DISCOVERY
- A phase I study of larotaxel (XRP9881) administered in combination with carboplatin in chemotherapy-naïve patients with stage IIIB or stage IV non-small cell lung cancer
- (2009) Francisco Robert et al. CANCER CHEMOTHERAPY AND PHARMACOLOGY
- Phase I and Pharmacokinetic Study of XRP6258 (RPR 116258A), a Novel Taxane, Administered as a 1-Hour Infusion Every 3 Weeks in Patients with Advanced Solid Tumors
- (2009) A. C. Mita et al. CLINICAL CANCER RESEARCH
- Larotaxel: broadening the road with new taxanes
- (2009) Otto Metzger-Filho et al. EXPERT OPINION ON INVESTIGATIONAL DRUGS
- Transport characteristics of a novel peptide platform for CNS therapeutics
- (2009) Yanick Bertrand et al. JOURNAL OF CELLULAR AND MOLECULAR MEDICINE
- Recent Advances in the Chemistry and Biology of New Generation Taxoids‡
- (2009) Iwao Ojima et al. JOURNAL OF NATURAL PRODUCTS
- A multicenter phase II study of XRP6258 administered as a 1-h i.v. infusion every 3 weeks in taxane-resistant metastatic breast cancer patients
- (2008) X. Pivot et al. ANNALS OF ONCOLOGY
- A clinical study on the premedication of paclitaxel liposome in the treatment of solid tumors
- (2008) Qian Zhang et al. BIOMEDICINE & PHARMACOTHERAPY
- Phase III trial comparing paclitaxel poliglumex vs docetaxel in the second-line treatment of non-small-cell lung cancer
- (2008) L Paz-Ares et al. BRITISH JOURNAL OF CANCER
- In Reply
- (2008) Tomasz M. Beer JOURNAL OF CLINICAL ONCOLOGY
- Design, Synthesis, and Biological Evaluation of New-Generation Taxoids
- (2008) Iwao Ojima et al. JOURNAL OF MEDICINAL CHEMISTRY
- Functionalized Single-Walled Carbon Nanotubes as Rationally Designed Vehicles for Tumor-Targeted Drug Delivery
- (2008) Jingyi Chen et al. JOURNAL OF THE AMERICAN CHEMICAL SOCIETY
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExploreBecome a Peeref-certified reviewer
The Peeref Institute provides free reviewer training that teaches the core competencies of the academic peer review process.
Get Started